Sanofi

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company is engaged in creating first-in-class immunotherapy drug candidates, leveraging its proprietary platform to harness the innate immune system. Key products in its pipeline include Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody also in Phase II for cutaneous T-cell lymphoma. Additionally, the pipeline features various candidates at different stages, including IPH5201 and IPH5301, which target immunosuppressive pathways. Innate Pharma has established licensing and collaboration agreements with major pharmaceutical companies, enhancing its research and development capabilities. Founded in 1999, the company operates internationally, contributing to the advancement of cancer treatment through innovative therapeutic approaches.

Enveda Biosciences is a biotechnology company focused on drug discovery through the exploration of chemical diversity found in nature. Utilizing AI-powered tools, the company develops a robust database of chemical molecules derived from living organisms. Enveda's platform integrates machine learning, metabolomics, and robotics to analyze natural samples for their chemical structures and biological activities. This innovative approach allows for the efficient identification of potential new medicines, including antibiotics and hypotensives, without the need for isolating individual compounds or conducting extensive experiments. By harnessing nature's hidden chemistry, Enveda aims to accelerate the development of novel therapeutics for the healthcare industry.

Zucara Therapeutics Inc. is a biotechnology company based in Toronto, Canada, with an additional office in Vancouver. Founded in 2014, the company focuses on developing innovative therapeutics aimed at preventing hypoglycemia, or low blood sugar, in patients with diabetes. Its lead pre-clinical technology targets somatostatin type 2 receptors in the pancreas, which are inadequately regulated in individuals with Type 1 diabetes. By blocking these receptors, Zucara's treatment aims to prevent hypoglycemia and restore natural glucose levels in the bloodstream. This approach represents a significant advancement over existing therapies, which typically only address hypoglycemia after it has occurred, rather than preventing it from happening in the first place.

Resalis Therapeutics is a biopharmaceutical company focused on transforming the treatment of metabolic diseases, particularly obesity and fatty liver disease, by developing innovative therapies that target key regulatory pathways. The company's leading program, RES-010, utilizes its expertise in non-coding RNA drug modalities and lipid metabolism to create a treatment that aims for long-term weight loss and reduced liver fat accumulation. With a strong foundation of preclinical evidence, Resalis is progressing RES-010 into clinical trials, offering potential disease-modifying effects and a safe, convenient therapeutic option for patients suffering from various metabolic disorders.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Vicore Pharma is a clinical-stage pharmaceutical company dedicated to developing innovative treatments for severe lung disorders, particularly idiopathic pulmonary fibrosis (IPF). The company's lead drug candidate, C21, is a small molecule angiotensin II type 2 receptor agonist currently in phase 2a development and has received orphan drug designation in both the EU and the US. C21 is also being explored for potential applications in other rare diseases associated with the AT2 receptor. In addition to its pharmacological efforts, Vicore Pharma is developing Almee, an investigational medical device that employs cognitive behavioral therapy to address the psychological challenges faced by patients with pulmonary fibrosis. The company operates from Astra Zeneca’s Bioventurehub in Mölndal.

Kasha is an e-commerce platform based in Kigali, Rwanda, that focuses on providing accessible personal care and health products for women in Rwanda and Kenya. Founded in 2016, Kasha offers a wide range of products, including bath and body items, menstrual care supplies such as sanitary pads and tampons, and sexual health products including contraceptives and lubricants. The company also provides pharmaceuticals, pain relievers, supplements, and mom and baby care products. Kasha aims to promote health for women at all stages of life, addressing needs related to maternal health, menstrual hygiene, family planning, and chronic diseases. By operating both online and in urban and rural areas, Kasha seeks to enhance accessibility to essential health and personal care products.

AnaptysBio is a privately-held therapeutic antibody product company that uses of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease. The Company's SHM-Platform utilizes the key components of SHM and other techniques to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection a process that has been referred to as naturalizing antibodies. This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties. In addition to providing a more powerful approach to antibody discovery and protein optimization, it addresses a growing void in the therapeutic antibody field due to a string of acquisitions and licensing deals that have reduced the availability of many technologies.

Mirador Therapeutics envisions precision medicine for immune-mediated inflammatory and fibrotic diseases.

Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication of improving lung function and is found in several asthma-related treatments.

Inhibrx, Inc. is a clinical-stage biotechnology company based in La Jolla, California, dedicated to developing a diverse pipeline of novel biologic therapeutic candidates. The company employs advanced protein engineering techniques, including its proprietary sdAb platform, to target complex disease biology, with a focus on oncology, orphan diseases, and infectious diseases. Inhibrx's lead candidates include INBRX-109, a multivalent agonist in Phase 1 trials for solid tumors; INBRX-105, an antagonist of PD-L1 also in Phase 1 trials; INBRX-101, an Fc-fusion protein for alpha-1 antitrypsin deficiency; and INBRX-103, a monoclonal antibody targeting CD47. Additionally, the company is developing preclinical programs such as INBRX-106, an agonist of OX40, and INBRX-111, an antibody targeting Pseudomonas aeruginosa. Inhibrx has established collaborations with organizations like Celgene and Bluebird Bio and has received funding from various granting agencies, including the NIH and CARB-X.

We are a pharmaceutical company dedicated to improving access to medicine in East & Central Africa. We mainly focus on data-driven healthcare solutions that increase access and quality of information as well as facilitate safe, effective, and sustainable pharmaceutical supply chains across the industry. Our mission is to increase access to high-quality medicines, services, and information via technology solutions that improve affordability, health outcomes, and ease of use.

Graviton Bioscience is a clinical-stage drug discovery and development firm focused on creating and developing therapies for the treatment of CNS, autoimmune, fibrotic, and other significant disorders in which ROCK2 plays a critical role in pathology.

Qunol meets a variety of nutritional requirements as determined by a cardiologist. The recommended form of CoQ10 is the absorption turmeric compound curcumin. They received professional medical advice, diagnosis, or treatment. They offer supplements offering both ubiquinone and ubiquinol, as well as turmeric supplements to support health.

Provention Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's product candidates include PRV-031, a monoclonal antibody currently in Phase III clinical trials for the interception of type 1 diabetes, and PRV-6527, an oral CSF-1R inhibitor in Phase IIa trials for Crohn's disease. Additionally, PRV-3279 has completed Phase 1b trials for lupus, while PRV-101 is being developed as a vaccine for coxsackie virus B infections, which may prevent the onset of type 1 diabetes. Provention Bio also has a licensing agreement with Amgen for PRV-015, a monoclonal antibody targeting celiac disease. Founded in 2016 and based in Oldwick, New Jersey, Provention Bio aims to address the high morbidity and costs associated with chronic autoimmune and inflammatory diseases through its innovative predictive and preventive therapeutic approaches.

Provention Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's product candidates include PRV-031, a monoclonal antibody currently in Phase III clinical trials for the interception of type 1 diabetes, and PRV-6527, an oral CSF-1R inhibitor in Phase IIa trials for Crohn's disease. Additionally, PRV-3279 has completed Phase 1b trials for lupus, while PRV-101 is being developed as a vaccine for coxsackie virus B infections, which may prevent the onset of type 1 diabetes. Provention Bio also has a licensing agreement with Amgen for PRV-015, a monoclonal antibody targeting celiac disease. Founded in 2016 and based in Oldwick, New Jersey, Provention Bio aims to address the high morbidity and costs associated with chronic autoimmune and inflammatory diseases through its innovative predictive and preventive therapeutic approaches.

SwipeRx is a digital platform designed to enhance the operations of pharmacies by connecting pharmaceutical manufacturers, pharmacies, and patients. It offers a range of services, including specialized healthcare logistics, negotiated pricing, and financing solutions, creating a robust network for pharmacy purchasing. The platform generates insights that facilitate collaboration with pharmacies, improve pharmacist education, and strengthen market access. Additionally, it optimizes commercial strategies and enhances daily operational efficiencies. By providing real-time access to patient and sell-out data, SwipeRx enables its clients to improve patient affordability, access, and adherence to medications.

Livmed's is a software platform that provides home medicine delivery services for fellow citizens and healthcare players. The company was founded in 2020 and is headquartered in Nice, France.

Innovent Biologics, Inc. is a leading biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacture, and commercialization of monoclonal antibodies. The company focuses on various therapeutic areas, including oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody used in the treatment of several cancers, including Hodgkin’s lymphoma and esophageal carcinoma. Innovent is also developing a range of additional drug candidates, such as biosimilars for rituximab and adalimumab, as well as novel monoclonal antibodies targeting conditions like hypercholesterolemia and different types of cancer. With a robust pipeline and over 30 strategic collaborations with global pharmaceutical companies, Innovent is well-positioned in the biopharmaceutical landscape. The company's founders and management team bring extensive experience in biologics, having participated in the launch of notable products across international markets. Innovent was founded in 2011 and has established itself as a prominent player in the biotechnology sector in China.

Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication of improving lung function and is found in several asthma-related treatments.

Origimm is an Austrian biotechnology company, which specializes in discovery of antigens and functional drug targets.

Owkin is an artificial intelligence company founded in 2016 with offices in New York and Paris, focused on improving patient outcomes through innovative technology. The company utilizes AI to enhance drug discovery and development, particularly in oncology, by identifying new drug candidates, de-risking clinical trials, and creating diagnostic tools. Owkin's offerings include Okwin Lab, which connects data by therapeutic area; Okwin Loop, which features validated models; and a comprehensive software stack for full-service solutions. The company employs federated learning, enabling collaboration among medical and biopharma partners to extract insights from disparate datasets while safeguarding patient privacy. Owkin has developed a catalog of 30 validated models, with an additional 40 in development, and has raised over $255 million in funding, achieving unicorn status in November 2021. Co-founded by Thomas Clozel and Gilles Wainrib, Owkin aims to transform the landscape of healthcare by delivering tailored treatments for individual patients.

Kadmon is a biopharmaceutical company focused on discovering, developing, and commercializing small molecules and biologics for the treatment of inflammatory and fibrotic diseases. The company’s lead product candidates include KD025, an oral selective inhibitor targeting rho-associated coiled-coil kinase 2, currently in Phase II clinical trials for chronic graft-versus-host disease and fibrotic conditions. Other significant candidates are KD045, also an oral inhibitor for fibrotic diseases, and KD033, an anti-PD-L1/IL-15 fusion protein aimed at cancer treatment. Kadmon is also developing Tesevatinib for autosomal dominant polycystic kidney disease and provides ribavirin for hepatitis treatment. The company offers patient assistance programs and other support services to enhance treatment access and adherence. Founded in 2010 and headquartered in New York, Kadmon has established strategic collaborations and license agreements to further its research and development efforts.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and based in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed to treat ornithine transcarbamylase deficiency. Translate Bio aims to create innovative medicines that have the potential to significantly impact the treatment landscape for rare diseases.

Tidal Therapeutics is a preclinical biotech company based at LabCentral in Cambridge, MA. The company is focused on developing nanoparticles that deliver mRNA to reprogram immune cells inside the body with applications in oncology and immune diseases.

novadiscovery is a developer of a drug discovery platform in silico clinical trials designed to de-risk, optimize research and development along with curbing the cost of discovering new drugs. The company's platform uses mathematics and intelligent algorithms to build a community of virtual patients as on-demand digital lab rats, enabling scientists and biotech, pharma companies to predict drug efficacy and create the target combination.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, the Netherlands, specializing in cell-based immunotherapy products aimed at treating blood cancers and inherited blood disorders. The company is currently advancing K-NK002, which is undergoing Phase II clinical trials for blood cancer patients receiving haploidentical hematopoietic stem cell transplants with the post-transplant cyclophosphamide protocol. Additionally, Kiadis Pharma is developing K-NK003, currently in Phase I/II trials for patients with acute myeloid leukemia relapse or refractory cases. The preclinical product pipeline includes K-NK00X, a natural killer (NK) cell therapy candidate targeting various solid tumors. Kiadis Pharma also collaborates with several institutions, including Harbour BioMed and Erasmus Medical Center, to explore a combination of monoclonal antibodies and natural killer cells as a potential treatment for COVID-19. Founded in 1997, Kiadis Pharma is committed to addressing significant unmet medical needs in the treatment of blood-related conditions.

Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.

Synthorx, Inc. is a biopharmaceutical company based in La Jolla, California, focused on developing innovative cytokine Synthorin programs for the treatment of cancer and autoimmune disorders. The company's lead product candidate, THOR-707, is a variant of recombinant human IL-2 being explored for various solid tumors, both as a standalone treatment and in combination with immune checkpoint inhibitors. Additionally, Synthorx is working on IL-2 Synthorin for autoimmune conditions, IL-10 Synthorin for immuno-oncology, and IL-15 Synthorins to enhance immune regulation. The company employs advanced synthetic biology techniques, utilizing a novel DNA base pair to create proteins with enhanced specificity, safety, and efficacy. These developments enable the manufacturing of improved therapeutics that can better modulate pharmacological properties compared to traditional biologics. Synthorx, which was established in 2014 and previously known as Alinos, Inc., operates as a subsidiary of Sanofi and holds exclusive rights to its innovative synthetic biology technology derived from research at The Scripps Research Institute.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines using its innovative virus-like particle (VLP) technology platform, which allows for the multivalent display of complex viral antigens. This technology aims to provide broad and durable protection against various infectious diseases, with an initial focus on life-threatening respiratory illnesses. Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2. The company is dedicated to advancing its VLP technology to discover, develop, and ultimately commercialize effective vaccines against these infectious diseases.

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.

Aetion, Inc. is a healthcare analytics company that specializes in generating real-world evidence (RWE) through its Aetion Evidence Platform. This platform analyzes data from diverse clinical and financial interactions within the healthcare system, including claims, electronic health records, and clinical trials. By utilizing its patented rapid-cycle analytics technology, Aetion provides valuable insights to life sciences companies, payers, and healthcare providers, enabling them to assess the effectiveness and value of medical treatments. This facilitates collaboration among stakeholders to make informed decisions regarding patient care that is both clinically effective and cost-efficient. Founded in 2012 and headquartered in New York City, Aetion has established partnerships with various investors and organizations, including a strategic collaboration with McKesson. The company caters to a global clientele, including biopharmaceutical firms and academic institutions.

BioNTech is a biotechnology company based in Germany that specializes in developing innovative therapies for cancer and infectious diseases, including COVID-19. The company is known for its focus on individualized immunotherapy and has a diverse oncology pipeline that features various classes of drugs, such as mRNA-based therapeutics that encode antigens and neoantigens, as well as cytokines, antibodies, cell therapies, bispecific antibodies, and antibody-drug conjugates. BioNTech's notable achievement includes the commercialization of its COVID-19 vaccine, Comirnaty. Additionally, the company collaborates with several major pharmaceutical firms, enhancing its capabilities and reach in the biopharmaceutical industry.

Enable Injections, LLC specializes in the design and manufacture of disposable, body-worn bolus injectors that facilitate the delivery of high viscosity and volume injectable drugs directly into subcutaneous tissue. Established in 2010 and based in Cincinnati, Ohio, the company’s innovative devices can utilize standard containers such as vials, syringes, or cartridges. These injectors not only allow for the reconstitution of powdered drugs but also enable the delivery of up to 20 ml of medication. The system automatically warms and mixes lyophilized solutions, ensuring a seamless injection experience. Additionally, Enable Injections offers a version of its platform that can connect to smartphones via Bluetooth, enhancing user interaction. With approximately 900 new drugs in development that may benefit from this technology, the market for bolus injection systems is projected to reach $8 billion within the next decade.

Eden Biologics, formerly known as JHL Biotech, is a biopharmaceutical company that specializes in the development of biosimilars and offers contract development and manufacturing services to various clients and partners. The company focuses on producing a diverse range of complex dosage forms, including oral solid, liquid, and semi-solid products, as well as macromolecule biologics. By leveraging its expertise in both global and regional regulatory affairs, Eden Biologics aims to make biopharmaceuticals more affordable and accessible to patients worldwide. Through its comprehensive services, the company supports the entire process from cell line development to commercial manufacturing, enhancing the efficiency and effectiveness of biopharmaceutical development for its partners.

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapies for patients with rare genetic diseases. The company is dedicated to addressing unmet medical needs, particularly in the realm of genetically defined conditions. Its lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a progressive muscle-wasting disorder. Additionally, Fulcrum is developing FTX-6058, aimed at increasing fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia. The company also engages in research to identify drug targets for various conditions, including Duchenne muscular dystrophy and neurological diseases. Fulcrum Therapeutics has established collaborations with Acceleron Pharma Inc. and MyoKardia, Inc. to explore new therapeutic avenues in pulmonary disease and genetic cardiomyopathies, respectively. Founded in 2015, Fulcrum aims to enhance the quality of life for patients suffering from these challenging disorders.

Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a unique class of therapeutic proteins derived from single-domain antibody fragments. These innovative proteins are designed to address a variety of serious human diseases, including inflammation, hematology, oncology, and pulmonary conditions. Currently, Ablynx has around 25 projects in its pipeline, with five Nanobodies in clinical development. By combining the advantages of traditional antibodies and small chemical molecules, Ablynx aims to provide new therapeutic options that can significantly improve patient care and outcomes.

Thermalin, Inc. is a biotechnology company based in Cleveland, Ohio, founded in 2010, that specializes in developing innovative insulin therapies for individuals with Type 1 and Type 2 diabetes. The company aims to disrupt the insulin and insulin delivery market with its first-in-class, ultra-rapid acting insulin, which is stabilized and highly concentrated. This new insulin formulation is designed for use in a disposable, postage-stamp-sized glucose management system and can also be utilized in existing insulin pumps. In addition to its lead program, Thermalin is exploring partnerships to develop no-cold-chain basal and mix insulins, as well as glucose-responsive insulins. By creating insulin analogs that do not require refrigeration and are rapidly absorbed, Thermalin seeks to reduce the burden of insulin therapy, thereby improving patient adherence and health outcomes.

Eden Biologics, formerly known as JHL Biotech, is a biopharmaceutical company that specializes in the development of biosimilars and offers contract development and manufacturing services to various clients and partners. The company focuses on producing a diverse range of complex dosage forms, including oral solid, liquid, and semi-solid products, as well as macromolecule biologics. By leveraging its expertise in both global and regional regulatory affairs, Eden Biologics aims to make biopharmaceuticals more affordable and accessible to patients worldwide. Through its comprehensive services, the company supports the entire process from cell line development to commercial manufacturing, enhancing the efficiency and effectiveness of biopharmaceutical development for its partners.

Onduo is a digital healthcare company based in Cambridge, Massachusetts, focused on improving the lives of individuals with chronic conditions, particularly hypertension and type 2 diabetes. The company provides diabetes treatment services that encompass both the development of pharmaceutical drugs and digital tools aimed at enhancing medication management. By leveraging data, Onduo empowers individuals to make informed decisions about their daily health, promoting better habits and health goals.

Portal Instruments, Inc. is a clinical-stage medical device company based in Cambridge, Massachusetts, specializing in needle-free drug delivery systems. Founded in 2012, the company designs and manufactures jet injectors that administer medications through the skin using a narrow stream, allowing for precise delivery at specific depths and volumes. This innovative technology aims to enhance the patient experience by providing a painless, silent, and safe alternative to traditional needles and syringes. Portal Instruments' platform is compatible with a wide range of pharmaceutical manufacturing processes and is designed to accommodate various medical, animal, agricultural, and cosmetic applications. The company's goal is to become the standard for modern drug delivery, transforming how medications are administered to patients with chronic diseases.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases. Founded in 2012 and headquartered in Brisbane, California, the company primarily addresses heritable cardiomyopathies and genetically-driven heart failure caused by biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, an orally administered small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company also has several preclinical programs, including MYK-224 for HCM, ACT-1 for diastolic dysfunction, and LUS-1 for diastolic dysfunction. As of late 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

Elder Pharmaceuticals Limited is a Mumbai-based company that manufactures and markets prescription pharmaceuticals and medical devices both in India and internationally. Established in 1983, it offers a diverse range of products across therapeutic areas, including nutraceuticals, anti-infectives, pain management, and lifestyle disorders. The company's product portfolio features antibiotics, central nervous system (CNS) medications, cardiovascular (CVS) treatments, gastrointestinal (GI) solutions, gynecological products, anti-inflammatory agents, and more. These offerings are available in various dosage forms, such as tablets, capsules, syrups, injectables, and topical applications. Elder Pharmaceuticals is recognized for its strategic alliances and an extensive marketing and distribution network, which enables it to provide affordable healthcare solutions to patients, particularly in smaller towns and villages.

Pluromed, Inc. develops, manufactures, and markets disposable medical devices based on reverse thermosensitive polymer technology in Europe, Canada, and the United States. It offers LeGoo Internal Vessel Occluder, a liquid polymer for the temporary occlusion of blood vessels; and LeGoo Endovascular Occlusion Gel for clampless vascular and cardiovascular surgery. The company also provides BackStop, an atraumatic device to prevent stone migration and stone fragment retropulsion during ureteroscopic lithotripsy; and Lumagel, an oncology product for cancer therapies, partial nephrectomy, hepatic resection, radiofrequency ablation, and chemotherapy. Its products are used to control bleeding during various surgical and interventional procedures including cardiac and vascular surgery, plastic and reconstructive surgery, kidney and liver cancer therapies, and trauma/battlefield injuries. The company was founded in 2003 and is based in Woburn, Massachusetts. As of April 2, 2012, Pluromed, Inc. operates as a subsidiary of Sanofi.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of antibiotics aimed at treating bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which target acute bacterial skin infections and gram-negative pathogens. Melinta's mission is to address the urgent need for effective antibiotics to combat drug-resistant infections, a significant public health challenge. The company is actively advancing its late-stage investigational antibiotic, delafloxacin, currently in Phase 3 development for acute bacterial skin and skin structure infections. Additionally, Melinta is engaged in research aimed at developing new antibiotics to tackle resistant pathogens associated with serious hospital-acquired infections. Melinta Therapeutics maintains license agreements with several institutions, including Yale University and Wakunaga Pharmaceutical Co., Ltd., and is supported by investors such as Vatera Healthcare Partners and Warburg Pincus.

Warp Drive Bio, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on developing genomic technology to discover drugs of natural origin. Founded in 2010, the company utilizes a proprietary genomic search engine and customized search queries to uncover hidden natural products by analyzing their unique genomic signatures. This innovative approach allows researchers to generate novel drug candidates and understand their mechanisms of action, facilitating the conversion of genomic data into potential therapeutic drugs. As of October 2018, Warp Drive Bio operates as a subsidiary of REVOLUTION Medicines, Inc.

Esperance Pharmaceuticals Inc. is a biotechnology company based in Houston, Texas, focused on developing targeted anticancer drugs for women with ovarian and breast cancer. The company's key product, EP-100, is an oncolytic peptide designed to selectively bind to receptors for luteinizing hormone releasing hormone (LHRH) found on cancer cells, enabling it to destroy these cells while sparing normal tissue. This innovative approach allows the drug to effectively target both dividing and non-dividing cancer cells, including those resistant to traditional chemotherapy. Esperance has formed a strategic alliance with MD Anderson Cancer Center to expedite the clinical development of EP-100, further enhancing its commitment to advancing cancer treatment. The company was incorporated in 2005 and is dedicated to improving outcomes for patients through its novel therapeutic strategies.

KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment options for cancer and autoimmune disorders.

Nepentes Pharma Sp. z o.o. is a pharmaceutical company focused on the manufacturing and distribution of various healthcare products, including Iwostin, Emolium, Elixine, Propodia, ApiPanten, Propolki, and Propolets. The company is dedicated to enhancing brand presence in pharmacies by coordinating the development, implementation, and oversight of effective marketing strategies. Operating primarily in Central and Eastern Europe, Nepentes Pharma aims to provide high-quality products while ensuring optimal market performance through comprehensive business activities.

Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company based in San Diego, California, specializing in the discovery and development of therapies that target microRNAs for various diseases. The company is advancing its lead product candidates, RG-012 and RGLS4326, which are in Phase II and Phase Ib clinical trials, respectively. RG-012 targets miR-21 for the treatment of Alport syndrome, a severe kidney disease, while RGLS4326 targets miR-17 for autosomal dominant polycystic kidney disease. In addition to these candidates, Regulus is developing a pipeline of preclinical drug products, including RGLS5579, aimed at inhibiting miR-10b, as well as programs targeting hepatitis B virus and non-alcoholic steatohepatitis. Founded in 2007, Regulus Therapeutics is at the forefront of leveraging the therapeutic potential of microRNA, a significant scientific breakthrough in recent years.

TargeGen, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in the discovery and development of small molecule kinase inhibitors targeting vascular leakage, angiogenesis, and inflammation. Founded in 2002, TargeGen focuses on creating treatments for various serious medical conditions, including heart attacks, cancer, and eye diseases. The company's products address issues such as vascular leakage, edema, the abnormal growth of new blood vessels, and conditions like pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome, brain inflammation, and hypovolemia. TargeGen also serves specific markets related to macular degeneration, diabetic macular edema, and diabetic retinopathy. The company was acquired in 2010, which has further enhanced its capabilities in addressing critical health challenges.

Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.

Shantha Biotechnics, established in 1993 by Dr. Varaprasad Reddy and based in Hyderabad, India, specializes in the development, manufacturing, and marketing of vaccines. Operating in a state-of-the-art facility that meets international standards, the company has collaborated with organizations such as UNICEF and PAHO to supply vaccines to major markets across Asia-Pacific, Africa, and Latin America. Shantha is notable for launching SHANVAC-B™, the first recombinant Hepatitis B vaccine produced in India in 1997. Its product line includes SHANVAC-B™, SHANTETRA™ (a combination vaccine for Diphtheria, Pertussis, Tetanus, and Hepatitis B), SHAN5™ (a combination vaccine for Diphtheria, Pertussis, Tetanus, Haemophilus influenza B, and Hepatitis B), and SHANTT™ (a Tetanus toxoid vaccine), all of which are prequalified by the World Health Organization for global distribution to United Nations agencies. Additionally, Shantha has a significant portfolio of vaccines that are currently in development.

Merial Limited is an animal healthcare company specializing in the research, development, and production of pharmaceutical products and vaccines for livestock, pets, and wildlife. The company offers a range of products in various medical fields, including anaesthetic, antiparasitic, antimicrobial, gastrointestinal, respiratory, and cardiovascular medicines. Notable products include IVOMEC for treating parasites in cattle, sheep, and swine, and FRONTLINE for pets. Merial's vaccines address significant diseases affecting animals, such as Newcastle Disease and Avian Flu. The company serves a diverse clientele, including veterinarians, pet owners, farmers, and food animal producers globally. Founded in 1997 as a joint venture between the animal health divisions of Rhône-Poulenc and Merck, Merial is headquartered in Duluth, Georgia, and operates in multiple countries worldwide. It is a subsidiary of Sanofi-Aventis, which acquired Rhône-Poulenc and later took over Merck's stake in the company.

BiPar Sciences Inc., based in Brisbane, California, is focused on developing PARP inhibitors as therapies for various cancers. The company's primary experimental product, BSI-201, is undergoing mid-stage trials for advanced breast cancer, ovarian cancer, and other tumors, particularly those that are therapy-resistant or difficult to treat. In addition to BSI-201, BiPar is working on a follow-on inhibitor candidate for pancreatic cancer and an iodothyronine program that possesses anti-tubulin properties, which could enhance the effectiveness of chemotherapy. BiPar has raised approximately $60 million in venture capital from several prominent investment firms and has also secured venture debt. In April 2009, the company announced its acquisition by a French pharmaceutical company for up to $500 million.

Medley, the third-largest pharmaceutical firm in Brazil, and the number one generic drugs group in the country.

Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

E-Markets, founded in 1996 and based in Berthoud, Colorado, specializes in providing web-based software solutions tailored for the agribusiness industry. The company's offerings include tools for ordering, price risk management, inventory management, procurement, and traceability, all designed to meet the specific needs of agribusiness processes. E-Markets collaborated with Microsoft in 2002 to develop a new operational system utilizing a .Net framework, resulting in the creation of CINCH® and Intellego. These solutions integrate with Microsoft Dynamics GP financials to deliver comprehensive accounting services across various agribusiness sectors, including grain, seed, and fertilizer. By enhancing operational efficiencies, E-Markets supports ag retailers, processors, seed companies, and cooperatives in improving their financial performance.

It is a pharmaceutical company